Phase II Study of Gemcitabine, Oxaliplatin, and Cetuximab in Advanced Pancreatic Cancer

Jaime R. Merchan(Sylvester Comprehensive Cancer Center), Caio Rocha‐Lima(University of Miami), Kristen K. Ciombor(Vanderbilt University Medical Center), Aurea M. Flores(Sylvester Comprehensive Cancer Center), Gilberto Lopes(University of Miami), J. A. Levi(University of Miami), Jessica MacIntyre, Danny Sleeman(University of Miami), Annaporna Ferrell(Sylvester Comprehensive Cancer Center), Afonso Ribeiro(University of Miami)
American Journal of Clinical Oncology
May 6, 2011
10.1097/coc.0b013e31821862fb
Cited by 21

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|998
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|846
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
|Journal of Clinical Oncology|2022|334